Corporate | 24 September 2007 17:00
STRATEC Biomedical Systems AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
STRATEC participates in Capital Market Conferences
Birkenfeld, September 24, 2007
STRATEC Biomedical Systems AG has announced today that the company will
participate in Fall 2007 in several significant Capital Market Conferences
specializing in the MedTech and Healthcare fields.
The start of the agenda was marked by the UBS Global Life Sciences
Conference which took place today in New York City, New York, USA. In his
presentation, Marcus Wolfinger, the Chief Financial Officer of STRATEC
Biomedical Systems AG explained the company’s business model to
institutional investors and spoke about the positive prospects for the
future of this field. A recording of the webcast can be viewed on the UBS
internet site at http://www.ibb.ubs.com.
STRATEC will also participate at the German Healthcare Conference on
October 2, 2007 in Zurich. This event will be hosted by BB MEDTECH, DZ BANK
AG, Hogan&Hartson, Viscardi AG and the Deutsche Börse.
Furthermore, on November 13, 2007, STRATEC will present to a number of
Capital Market participants within the framework of the event 'German
Equity Forum' in Frankfurt. The presentation will focus on the preliminary
figures of the first nine months of the fiscal year 2007, which will be
published by STRATEC prior to this conference.
STRATEC will conclude its scheduled participation in conferences in Fall
this year with the European Healthcare Conference, which will be held on
November 28, 2007 and hosted by HSBC Trinkaus & Burkhardt in London,
England.
Marcus Wolfinger, the Chief Financial Officer at STRATEC Biomedical Systems
AG said: 'By participating in investor conferences, we are able to reach
efficiently a number of important Capital Market investors at the same
time. Talking to potential investors at the respective events enables the
investors to get a deeper insight into matters relevant to the company.
Another point of focus of our investor relation activities lies in the
communication with our private shareholders, as it has also been in the
past.'
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and its subsidiaries STRATEC Biomedical Inc., STRATEC
NewGen GmbH, Robion AG and Sanguin International Ltd., as well as Sanguin
International Inc., a subsidiary of Sanguin International Ltd.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-mail: ir@stratec-biomedical.de
24.09.2007 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------